Horizon Pharma (NASDAQ:HZNP) was downgraded by equities research analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, The Fly reports.
Other equities research analysts have also issued research reports about the company. Stifel Nicolaus upped their price target on Horizon Pharma from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, June 18th. ValuEngine lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, July 5th. Cantor Fitzgerald set a $17.00 price target on Horizon Pharma and gave the company a “buy” rating in a research report on Wednesday, May 9th. Zacks Investment Research upgraded Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, July 10th. Finally, BidaskClub upgraded Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $19.73.
Shares of HZNP stock opened at $17.97 on Monday. Horizon Pharma has a twelve month low of $11.17 and a twelve month high of $18.23. The firm has a market cap of $2.97 billion, a P/E ratio of 15.23, a PEG ratio of 1.08 and a beta of 1.43. The company has a debt-to-equity ratio of 2.17, a quick ratio of 1.50 and a current ratio of 1.56.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.08). Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The company had revenue of $223.88 million during the quarter, compared to the consensus estimate of $232.05 million. During the same quarter last year, the firm posted $0.21 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. equities research analysts expect that Horizon Pharma will post 1.41 EPS for the current fiscal year.
In other news, Chairman Timothy P. Walbert sold 83,353 shares of the business’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $16.17, for a total value of $1,347,818.01. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Brian K. Beeler sold 15,433 shares of the business’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $17.58, for a total value of $271,312.14. The disclosure for this sale can be found here. Insiders sold a total of 116,717 shares of company stock worth $1,907,999 over the last three months. 3.90% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in HZNP. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Horizon Pharma by 74.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 3,877 shares during the period. D.A. Davidson & CO. acquired a new position in shares of Horizon Pharma in the 1st quarter valued at about $143,000. Zweig DiMenna Associates LLC acquired a new position in shares of Horizon Pharma in the 1st quarter valued at about $156,000. Macquarie Group Ltd. lifted its stake in shares of Horizon Pharma by 207.1% in the 4th quarter. Macquarie Group Ltd. now owns 12,900 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 8,700 shares during the period. Finally, Stevens Capital Management LP acquired a new position in shares of Horizon Pharma in the 1st quarter valued at about $195,000. 84.72% of the stock is currently owned by institutional investors.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Further Reading: Trading Penny Stocks
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.